To advance high-quality development on children’s health, to enough innovation on pediatric drugs, and to facilitate the transformation of research achievements, while strengthening communication among regulatory bodies, academic institutions and the pharmaceutical industry, the 4th Seminar on the Research and Development of Pediatric Drugs was successfully held in Beijing on June 6, 2025. This event was co-hosted by the Center for Drug Evaluation (CDE) and the China Center for Food and Drug International Exchange (CCFDIE) of NMPA.

　　The seminar emphasized that the CPC Central Committee places high importance on the healthy growth of children, advocating for the "children first" and children-friendly approach. In line with the instructions of the CPC Central Committee and the State Council, the NMPA remains committed to a people-centered philosophy, adhering to the principles of political commitment, enhanced regulation, safety assurance, development promotion, and public welfare. These efforts aim to deepen reforms and accelerate innovation and high-quality development in pediatric medicines.

　　Focused on themes such as "Advancing Rare Disease Drug Development to Safeguard Children's Health," "Addressing Challenges in Pediatric Rare Disease Treatment: Meeting Demand, Overcoming Clinical Trial Hurdles, and Fostering Multi-Stakeholder Collaboration," and "Progress and Challenges in Pediatric Rare Disease Drug R&D," the seminar featured insights from experts at the NMPA’s CDE, the National Center for Children's Medicine, renowned children’s hospitals, research institutions, and industry representatives. Attendees included representatives from relevant departments and institutions directly affiliated to NMPA.